MedTrace Logo

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

NCT07620574 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5000

Last updated 2026-06-02

No results posted yet for this study

Summary

The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.

Conditions

  • Cancer
  • Renal Cell Carcinoma (RCC)
  • Pancreatic Neuroendocrine Tumors (pNET)
  • Extra-Pancreatic NET (epNET)
  • Hepatocellular Carcinoma (HCC)
  • Differentiated Thyroid Cancer (DTC)
  • Non-Clear Cell Renal Cell Carcinoma (nccRCC)
  • Colorectal Cancer
  • Prostate Cancer

Interventions

DRUG

Cabozantinib

Administered as specified in the parent study.

DRUG

Zanzalintinib

Administered as specified in the parent study.

DRUG

Atezolizumab

Administered as specified in the parent study.

DRUG

Nivolumab

Administered as specified in the parent study.

DRUG

Abiraterone

Administered as specified in the parent study.

DRUG

Prednisone

Administered as specified in the parent study.

DRUG

Enzalutamide

Administered as specified in the parent study.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Exelixis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2030-05-31
Completion
2030-05-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07620574 on ClinicalTrials.gov